Pipeline Boasts First-in-Class Entries, Drugs in Crowded Areas
More and more of the pharma pipeline consists of specialty drugs. Going forward in 2020, areas that may see a lot of activity include biosimilars, orphan drugs and gene therapies, as well as potentially the first FDA-approved drug for Alzheimer’s and the first for nonalcoholic steatohepatitis (NASH).
More orphan drugs are expected to launch this year, continuing a trend examined in an issue brief by America’s Health Insurance Plans (AHIP) released in August 2019. Researchers found that 10% of all drug approvals in 1998 were orphan products, but by 2017, that percentage had risen to 44%.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’READ MORE